Abstract
Surface-enhanced Raman scattering (SERS) nanoparticles have been engineered to generate unique fingerprint spectra and are potentially useful as bright contrast agents for molecular diagnostics. One promising strategy for biomedical diagnostics and imaging is to functionalize various particle types (“flavors”), each emitting a unique spectral signature, to target a large multiplexed panel of molecular biomarkers. While SERS particles emit narrow spectral features that allow them to be easily separable under ideal conditions, the presence of competing noise sources and background signals such as detector noise, laser background, and autofluorescence confounds the reliability of demultiplexing algorithms. Results obtained during time-constrained in vivo imaging experiments may not be reproducible or accurate. Therefore, our goal is to provide experimentalists with a metric that may be monitored to enforce a desired bound on accuracy within a user-defined confidence level. We have defined a spectral reliability index (SRI), based on the output of a direct classical least-squares (DCLS) demultiplexing routine, which provides a measure of the reliability of the computed nanoparticle concentrations and ratios. We present simulations and experiments to demonstrate the feasibility of this strategy, which can potentially be utilized for a range of instruments and biomedical applications involving multiplexed SERS nanoparticles.
Introduction
The field of biomedical optics has traditionally approached disease detection by deducing tissue status through the measurement of optical signals generated either intrinsically by tissue constituents [1]–[12] or extrinsically by targeted probes with known signatures [13]–[23]. In particular, diagnostic approaches involving both intrinsic and extrinsic Raman scattering have seen much success owing to the sharp separable features of Raman spectra. Intrinsic Raman spectroscopy has been demonstrated to identify malignant tissues with high sensitivity and specificity [2], [6], [8], [10] and has also enjoyed the benefit of expedited regulatory approval since no external contrast agent is necessary. [8], [9], [11], [12]. However, the spectral features of diagnostic value in intrinsic Raman detection are generated by highly conserved chemical constituents such as hydrocarbon, lipid, or nucleic acid bonds, which may be difficult to relate to pathological or clinical variables. Additionally, the acquisition time for intrinsic Raman spectroscopy is necessarily long given the low efficiency of Raman scattering and therefore presents a practical challenge for clinical diagnostics and imaging.
Recently, a number of groups [13]–[19], [21], [23] have explored the use of surface-enhanced Raman-scattering (SERS) nanoparticles that are engineered to emit bright distinct spectra ( Fig. 1 ). These Raman-coded nanoparticles are available as different “flavors,” each emitting a characteristic spectral signature that may potentially be targeted against various molecular biomarkers for highly multiplexed molecular imaging. However, determining the reliability of particle concentrations or concentration ratios computed by spectral demultiplexing algorithms is a non-trivial challenge facing experimentalists since other signals such as detector noise, incomplete removal of excitation photons (laser background) and autofluorescence background degrade the accuracy of demultiplexing routines, especially as spectral overlap becomes a concern with increasing numbers of flavors competing within a limited spectral bandwidth.
Therefore, in this report, we propose a general method for quantifying the reliability of particle concentrations and ratios that are computed from a least-squares demultiplexing algorithm. First, this method is developed through numerical simulations of various mixtures of SERS nanoparticles in the context of noise and background signals. We define a metric, the spectral reliability index (SRI), which serves as a predictor of error in single- and multi-flavor applications. We further provide results from well-controlled experiments to assess the feasibility and accuracy of our approach. While initial experiments are intentionally simplified to verify the accuracy and reproducibility of these methods, our strategy could potentially be of value for a range of technologies that utilize targeted SERS-based nanoparticles to provide multiplexed measurements of molecular biomarkers both in vitro and in vivo.
Methods
Since our ultimate goal is to provide experimentalists with a reliable measure of nanoparticle concentrations or concentration ratios, we set out to simulate spectral measurements of SERS nanoparticles under the varying noise and background conditions that may be encountered experimentally. Simulated spectra were generated first for single-flavor applications, then for two-particle applications where the relative concentrations between particle flavors ranged from 1∶1 to 5∶1, and finally for two-flavor ratios within three-flavor mixtures. The rationale for a 5∶1 maximum range of relative nanoparticle concentrations is based on the observation that signal contrast between tumor and normal tissues rarely extends beyond a factor of five for in vivo preclinical and clinical molecular imaging studies [14], [24], [25].
It bears mentioning that actual measurements of SERS nanoparticles in cells and tissues can include endogenous Raman background signals from tissues as well as variable autofluorescence and laser background components. With this in mind, our study makes a few assumptions that are often relevant for biomedical spectroscopy with SERS nanoparticles: 1) background signals are spectrally broadband and do not contain sharp narrowband spectral features that are morphologically similar to the spectral peaks generated by SERS nanoparticles (i.e., we assume that endogenous Raman signals are orders of magnitude weaker than the signals from SERS nanoparticles); 2) since the Stokes shift of Raman signals is higher than fluorescence signals, autofluorescence background signals are due to the slowly varying (broadband) tail at the long-wavelength side of the autofluorescence spectra; 3) a significant amount of stray laser light contributes to a broadband background at the CCD detector despite efforts taken to filter out the illuminating laser radiation (see section 2.5).
2.1. Spectral Simulations
In order to simulate a realistic spectral measurement, pure spectra from single- or multi-flavor particle mixtures were mixed with varying magnitudes of broadband background signals and zero-mean Gaussian-distributed white noise (Eq. (1)). Note that Eq. (1) incorporates all broadband background signals (e.g. laser background and autofluorescence background) into a single spectral component, B. Furthermore, Eq. (1) combines shot noise and other stochastic noise sources (e.g., detector readout noise and dark counts) into a single Gaussian-distributed noise term, denoted δ. See Supplementary Material for example source code (Source S1).
(1) |
X = simulated spectrumcn = concentration of SERS nanoparticle n Fn = known reference spectrum of SERS nanoparticle flavor n k = scaling factor for background signal magnitudeB = known reference spectrum of broadband backgroundδ = noise
2.2. Demultiplexing SERS Spectra using DCLS
Other than sources of noise, it is assumed that each measured spectrum consists of a weighted sum of fixed nanoparticle spectra (Fn) and broadband background signals (B). Based on the assumption that the combination is linear, we employ a linear least-squares algorithm in MATLAB (MathWorks) to compute the relative nanoparticle weights (wn). A third-order polynomial is included to account for broadband background signals that are not captured by the broadband noise reference spectrum (B) [26]. See Supplementary Material for example source code (Source S2).
(2) |
S = measured spectral datawn = weight of SERS flavor n Fn = known reference spectrum of SERS nanoparticle flavor n k = scaling factor for background signal magnitudeB = known reference spectrum of broadband backgroundam = weight of m th-order polynomial termPm = m th-order polynomial term (for baseline correction)R = residual (minimized by least-squares algorithm)
2.3. Quality Metrics
Below we describe metrics called ‘relative fitting error’ (RFE) and ‘spectral reliability index’ (SRI). RFE and SRI are “goodness-of-fit” metrics that quantify how well the simulated spectra can be decomposed into the reference spectra defined a priori.
A common approach to quantify the reliability of a spectral fitting routine is to compare the norm of the fit to the norm of the input signal, a metric that has previously been termed the relative fitting error, RFE, given in Eq. (3) [27]. An RFE of 1 indicates a perfect fit and approaches zero as the fit degrades (i.e. the optimal fit lacks the ability to represent the input signal as a linearly weighted sum of the references supplied). However, in cases where the particle signals are weak in comparison to the broadband background signals, the reported RFE may be biased towards 1 due to the fact that the background and baseline signals are fit with high fidelity even if the fit for the nanoparticle components is poor. We therefore modify the RFE metric to ignore non-particle components so that they do not contribute to the apparent reliability of the least-squares fit. We call this modified measure the spectral reliability index (SRI), as shown in Eq. (4).
(3) |
(4) |
Although both RFE and SRI are informative consolidated measures of goodness of fit, the biomedical application of these fitting algorithms requires us to examine errors in the actual nanoparticle weights computed. For single-particle cases, we use the standard percent error definition. In cases with more than one particle, we compute each individual particle’s error and generate a single value that we call the composite error for the entire mixture (Eq. (5)). This will be discussed further in section 2.4.
(5) |
An example of the difference between RFE and SRI is shown in Fig. 2 . In this example, varying levels of noise, δ, are superimposed on a fixed-magnitude spectrum representing the pure Raman signals from two SERS nanoparticle flavors. In addition, these simulated spectra contain either a low magnitude of a broadband background, B, or an order-of-magnitude higher level of background, 10B. Increasing levels of noise (δ) in the simulated spectra result in degraded spectral quality and lower levels of the quality metrics, RFE and SRI. However, the simulation demonstrates that SRI is relatively insensitive to the magnitude of the broadband background. In contrast, the RFE is highly sensitive to the background level and is biased towards 1 when this background dominates the signal. In other words, the RFE does not provide a good indication of the “goodness-of-fit” of the SERS particles themselves. Rather, the RFE indicates a “goodness-of-fit” for a spectrum as a whole, which can be dominated by background components instead of the components of interest (SERS nanoparticles).
2.4. Measurement Error and Confidence
In an ideal situation, an experimentalist would obtain a single measurement and assume that the nanoparticle weights computed by a DCLS routine are accurate and reproducible in subsequent measurements. In reality, the randomness of the noise and broadband background signals results in a distribution of measurement errors. Thus, the goal of our simulations is to provide researchers with a minimum necessary SRI value to guarantee a maximum bound on concentration error (e.g., 10% error for any single measurement). To achieve this, a measure of confidence must be assigned to the maximum bound on concentration error that is desired for a single measurement. We first note that the concentration errors generated by the DCLS routine are normally distributed (Gaussian) for any single nanoparticle flavor. Second, we define a composite error for multi-flavor mixtures, which is the root-mean-squared error of all nanoparticle flavors (Eq. (5)). Defining the composite error in this way implies that the composite error for a mixture of nanoparticle flavors (n >1) is described by a gamma distribution [28].
In order to assign a level of confidence to the error of a single measurement that an experimentalist may perform, we simulate 50,000 spectral measurements corresponding to a particular SRI, process them through a DCLS demultiplexing routine, and then construct a histogram of concentrations errors (results shown later in section 3.2). After fitting a Gaussian (n = 1 flavor) or gamma (n >1 flavor) distribution to this histogram of concentration errors, the error value, e 80, corresponding to a certain percentile (in our case, 80%) of the cumulative distribution function is found. In other words, since 80% of the possible error values corresponding to a particular SRI are less than this error value, e 80, an experimentalist who has taken a single measurement and obtained an SRI value from the DCLS routine can be 80% confident that the error in their measurement is at most e 80 (results shown later in section 3.2).
2.5. In Vitro Experiments
Various flavors of SERS nanoparticles were obtained from Cabot Corporation, formerly Oxonica Materials (Mountain View, CA). Droplets (5 µL) of varying nanoparticle concentrations and mixtures between 0.8 and 800 pM were placed on a glass slide and point measurements were obtained using a custom fiberoptic probe (Fiberguide Industries, Stirling, NJ) that is angled at ∼45 degrees to the glass slide to minimize specular reflections. On the illumination side of the device, light from a 785-nm diode laser (30 mW) is first filtered with a narrow-bandpass filter (Semrock, LD01-785) prior to being coupled into the illumination fiber at the center of the fiber bundle. This removes off-resonant laser noise (including amplified spontaneous emission) that may be collected by the multimode fibers and contribute background signal and shot noise to the Raman spectra. Raman signals are collected via a bundle of 36 close-packed multimode fibers (200-µm core) surrounding one singlemode illumination fiber ( Fig. 3a ). These multimode fibers are reconfigured into an 8-mm tall linear array at the proximal end of the bundle, which serves as the entrance slit into a spectrometer.
Experiments are performed with a custom spectrometer from Bayspec (RamSpec NIR) outfitted with a cooled deep-depletion spectroscopic CCD (Andor DU920P-BR-DD). The Bayspec spectrograph utilizes low-f/# optics (f/1.8 or NA = 0.28) to effectively image Raman signals from the multimode collection fibers (NA = 0.21) onto a proprietary volume phase grating and then onto the Andor CCD. The Andor DU920P CCD contains 1024 x 256 pixels, with a 6.2-mm height (256-pixel dimension) that is exactly matched to the height of the image of our linear fiber bundle array with 4∶3 de-magnified imaging between the entrance slit and the CCD detector (the NA increases from 0.21 to 0.28). Since a large amount of the laser light (785-nm illumination wavelength) is collected by our multimode collection fibers, a relay extension is built into the front of the spectrograph to allow for the placement of a longpass interference filter (Semrock LP02-830RU-25) to reject illumination light at 785-nm, as well as any autofluorescence background at shorter wavelengths than the Raman peaks (<830-nm). This 4∶3 demagnification relay extension contains a 150-µm slit on the far end where the image of the linear array of fibers is refocused. This slit spatially filters out the diffuse stray light in the relay chamber from photons that are rejected by the longpass filter ( Fig. 3a ). However, this spatial filter is not perfect and still allows a significant amount of stray laser light into the spectrometer, which contributes to the broadband background seen by the CCD.
The reference spectra of the nanoparticles (Fn) as well as the background reference spectrum (B) are background-corrected to remove detector offset due to readout noise. Spectra are acquired through full-vertical binning of the pixels in each column of the CCD using the full dynamic range of the CCD sensor to minimize digitization noise. For experimental validation of simulations, particle concentrations are varied to monitor the effect of background and detector noise on the accuracy of demultiplexing. Note that at our measurement conditions (full vertical binning at 100 ms integration times), using a cooled detector at −65 deg C, detector readout noise dominates over dark counts (thermal noise). Deeper cooling may be necessary to suppress dark counts at longer integration times, at the expense of a slightly reduced quantum efficiency in the near infrared. Figs. 3b and 3c show two example spectra obtained experimentally at high and low particle concentrations, respectively, along with the least-squares fitted spectra (S). Note that in the low-concentration condition shown in Fig. 3c , the spectral features from the SERS nanoparticles are increasingly obscured by the broadband background and noise (detector readout noise and shot noise).
Results and Discussion
3.1. Single-flavor Concentrations: Simulations and Experiments
Experiments were first conducted with single nanoparticle flavors at various concentrations. Fig. 4a demonstrates the linearity of these measurements. Fig. 4b shows the normal distribution of errors for 5000 experimental measurements at a specific particle concentration. The shaded region indicates the range within which 80% of the errors lie (e 80). Finally, Fig. 4c shows how the percent error (at 80% confidence; e 80) varies as a function of SRI. A comparison between simulations and experiments ( Fig. 4c ) reveals excellent agreement and demonstrates the predictive power of the simulations. We find that for any single measurement in this particular experiment, spectral data with an SRI of 0.57 is necessary to guarantee an error ≤10% with 80% confidence.
3.2. Dual-flavor Concentrations: Simulations and Experiments
Next, a dual-flavor mixture is analyzed through simulations and experiments ( Fig. 5 ). In Fig. 5a , simulated histograms are shown of composite errors for a dual-flavor mixture of nanoparticles. Note that the composite-error histograms obey a gamma distribution, as described previously, and that we choose to use the 80th percentile (80% confidence level) for our analyses (e 80). By constructing composite-error histograms (e.g. Fig. 5a ) over a range of SRI conditions, we calculate how composite error varies as a function of SRI. In Fig. 5b , both a 1∶1 equimolar mixture as well as a 5∶1 mixture of particle flavors is simulated and experimentally validated at a range of concentrations (and subsequently a range of SRI values). Note that a higher SRI is required for a 5∶1 mixture, compared to a 1∶1 mixture, to guarantee an identical requirement for error of ≤10% with 80% confidence. This is due to the fact that in the 5∶1 case, although the lower-concentration flavor is fit with less fidelity than the higher-concentration flavor, the latter component dominates the overall spectrum and therefore dominates the SRI value as well. Fig. 5c is a plot (simulation) of the minimum SRI that is required to guarantee a composite error of ≤10% with 80% confidence, over a range of mixture ratios between two particle flavors (from 1∶5 to 5∶1). This plot shows how the minimum required SRI depends on the mixture ratio. In other words, in order to calculate the minimum SRI necessary to ensure a desired level of accuracy, one must also take into account the relative ratio of the particle flavors. This will be further elaborated in section 4 of this paper.
3.3. Triple-flavor Ratios: Simulations and Experiments
Finally, a triple-flavor mixture is investigated via simulations and experiments, and the error in the concentration ratios is presented ( Fig. 6 ). In practice, the ratio between various nanoparticle flavors is likely to be more important than absolute concentrations for in vivo molecular imaging studies. This is due to the fact that with both topical and systemic delivery, absolute particle concentrations are affected by a host of nonspecific effects, such as uneven particle delivery and washout of unbound probes, non-chemical enhanced-permeability-and-retention (EPR) effects, nonspecific chemical binding, as well as variations in optical alignment and working distance. Ratiometric measurements of particles targeted against various biomarkers that are referenced against nontargeted control particles offer the ability to quantify specific vs. nonspecific binding in spite of these confounding factors [29] as well as to quantify binding potentials [30]. Therefore, in a multiplexing application involving n targets, it is typically desirable to include an untargeted (nonspecific) negative control agent to serve as a single reference for the n targeted particles. Figure 6 demonstrates a three-particle simulation and experiment where one particle in the mixture (S440) is assumed to be a negative control for a weak target (S421) as well as a strong target (S420). The weak target does not exhibit elevated expression relative to the negative control (1∶1 ratio) whereas the strong target exhibits a 5-fold overexpression relative to the negative control.
Summary and Conclusions
In summary, we have presented an analysis of the accuracy of least-squares demultiplexing for spectral measurements of SERS particle mixtures. In particular, we have proposed and demonstrated the feasibility of a spectral reliability index (SRI) that correlates with measurement accuracy. The flowchart shown in Fig. 7 illustrates how the SRI may be employed to ensure desired measurement accuracy in a multiplexed molecular imaging study with SERS nanoparticles. The required inputs for this reliability analysis are: 1) raw spectra acquired from a Raman detection probe; 2) reference spectra (Fn) of nanoparticle flavors; 3) reference spectrum (B) of the background; and 4) a user-defined error threshold (a maximum error at a defined confidence level). A DCLS fitting algorithm takes the first 3 inputs listed above and computes a number of parameters, including the weights (wn) of the SERS particle flavors and the ratios between flavors. The results of the DCLS algorithm are also used to calculate an SRI for each spectral measurement according to Eq. (4). The main decision point depicted in the flowchart (purple diamond) involves taking the computed SRI, along with the computed particle ratios, to determine if the data satisfies the user-defined reliability criteria. Note that both the SRI and the particle ratios are needed to make this determination, as shown earlier in Fig. 5c , since measurement accuracy is a function of both.
In practice, a set of look-up tables could be generated through simulations in order to establish the relationships between error vs. SRI and particle ratios. This would allow one to rapidly assess the reliability of spectral demultiplexing measurements in real time. These simulations and look-up tables would be different for every device, experimental application (e.g., number of particle flavors), and user-defined error threshold since the relationship between error and SRI depends upon all of these instrument- and application-dependent factors. However, the general algorithm depicted in the flow chart in Fig. 7 applies for a range of applications utilizing SERS-coded nanoparticles for multiplexed molecular diagnostics. If spectral data do not satisfy the user-defined reliability criteria, the data may be discarded or the experiments may need to be repeated to improve the quality of the data, possibly through averaging or by changing system parameters (e.g., detector integration times, laser powers, etc.).
As SERS-coded nanoparticles gain popularity in animal studies and eventually for clinical diagnostics, the reliability of demultiplexing algorithms will need to be constantly assessed. Although spectroscopy is powerful in its ability to convey large amounts of information, performing accurate spectroscopic measurements is far from trivial. It has been our intent to develop a general metric and algorithm for rapidly assessing the experimental accuracy of spectral measurements involving multiplexed SERS nanoparticles. While we have performed simulations and experiments to demonstrate the basic feasibility of this approach using well-controlled experimental conditions under the simplifying assumptions mentioned in section 2, future studies are needed to demonstrate the accuracy and utility of these methods in a variety of biomedical applications such as in vitro diagnostics or in vivo molecular imaging.
Supporting Information
Acknowledgments
The authors thank Anushree Srivastava and Jack Zhou for technical support.
Funding Statement
This research was supported by the Office of the Vice President for Research at Stony Brook University, the United States National Institutes of Health (NIH)/NIBIB “Pathway to Independence” award – R00EB008557 (J.T.C. Liu) and R21EB015016 (Liu) from NIH/NIBIB. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1. Chang VTC, Bean SM, Cartwright PS, Ramanujam N (2010) Visible light optical spectroscopy is sensitive to neovascularization in the dysplastic cervix. Journal of biomedical optics 15: 057006–057006–057009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Haka AS, Volynskaya Z, Gardecki JA, Nazemi J, Shenk R, et al. (2009) Diagnosing breast cancer using Raman spectroscopy: prospective analysis. Journal of biomedical optics 14: 054023–054023–054028. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Paras C, Keller M, White L, Phay J, Mahadevan-Jansen A (2011) Near-infrared autofluorescence for the detection of parathyroid glands. Journal of Biomedical Optics 16: 067012–067012–067014. [DOI] [PubMed] [Google Scholar]
- 4. Praveen BB, Ashok PC, Mazilu M, Riches A, Herrington S, et al. (2012) Fluorescence suppression using wavelength modulated Raman spectroscopy in fiber-probe-based tissue analysis. Journal of Biomedical Optics 17: 077006–077001–077006–077006. [DOI] [PubMed] [Google Scholar]
- 5. Qiu L, Turzhitsky V, Chuttani R, Pleskow DK, Goldsmith JD, et al. (2012) Spectral Imaging with Scattered Light: From Early Cancer Detection to Cell Biology. Selected Topics in Quantum Electronics, IEEE Journal of 18: 1073–1083. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6. Vargis E, Tang YW, Khabele D, Mahadevan-Jansen A (2012) Near-infrared Raman Microspectroscopy Detects High-risk Human Papillomaviruses. Translational Oncology 5: 172. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7. Vishwanath K, Chang K, Klein D, Deng YF, Chang V, et al. (2011) Portable, fiber-based, diffuse reflection spectroscopy (DRS) systems for estimating tissue optical properties. Applied spectroscopy 65: 206–215. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Fenn MB, Xanthopoulos P, Pyrgiotakis G, Grobmyer SR, Pardalos PM, et al.. (2011) Raman Spectroscopy for Clinical Oncology. Advances in Optical Technologies 2011.
- 9. Bergholt MS, Zheng W, Lin K, Ho KY, Teh M, et al. (2011) In vivo diagnosis of gastric cancer using Raman endoscopy and ant colony optimization techniques. International journal of cancer 128: 2673–2680. [DOI] [PubMed] [Google Scholar]
- 10. Teh S, Zheng W, Ho K, Teh M, Yeoh K, et al. (2010) Near-infrared Raman spectroscopy for early diagnosis and typing of adenocarcinoma in the stomach. British Journal of Surgery 97: 550–557. [DOI] [PubMed] [Google Scholar]
- 11. Haka AS, Volynskaya Z, Gardecki JA, Nazemi J, Lyons J, et al. (2006) In vivo Margin Assessment during Partial Mastectomy Breast Surgery Using Raman Spectroscopy Cancer Research. 66: 3317–3322. [DOI] [PubMed] [Google Scholar]
- 12. Utzinger U, Heintzelman DL, Mahadevan-Jansen A, Malpica A, Follen M, et al. (2001) Near-Infrared Raman Spectroscopy for in Vivo Detection of Cervical Precancers. Applied spectroscopy 55: 955–959. [Google Scholar]
- 13. Doering WE, Piotti ME, Natan MJ, Freeman RG (2007) SERS as a foundation for nanoscale, optically detected biological labels. Advanced Materials 19: 3100–3108. [Google Scholar]
- 14. Jokerst JV, Miao Z, Zavaleta C, Cheng Z, Gambhir SS (2011) Affibody-Functionalized Gold–Silica Nanoparticles for Raman Molecular Imaging of the Epidermal Growth Factor Receptor. Small 7: 625–633. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15. Keren S, Zavaleta C, Cheng Z, De La Zerda A, Gheysens O, et al. (2008) Noninvasive molecular imaging of small living subjects using Raman spectroscopy. Proceedings of the National Academy of Sciences 105: 5844–5849. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Kircher MF, de la Zerda A, Jokerst JV, Zavaleta CL, Kempen PJ, et al. (2012) A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nature Medicine 18: 829–834. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Mohs AM, Mancini MC, Singhal S, Provenzale JM, Leyland-Jones B, et al.. (2010) A Handheld Spectroscopic Device for In Vivo and Intraoperative Tumor Detection: Contrast Enhancement, Detection Sensitivity, and Tissue Penetration. Analytical chemistry. [DOI] [PMC free article] [PubMed]
- 18. Qian X, Li J, Nie S (2009) Stimuli-responsive SERS nanoparticles: conformational control of plasmonic coupling and surface Raman enhancement. Journal of the American Chemical Society 131: 7540–7541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19. Qian X, Peng XH, Ansari DO, Yin-Goen Q, Chen GZ, et al. (2007) In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nature biotechnology 26: 83–90. [DOI] [PubMed] [Google Scholar]
- 20. Richards-Kortum R, Sevick-Muraca E (1996) Quantitative optical spectroscopy for tissue diagnosis. Annual review of physical chemistry 47: 555–606. [DOI] [PubMed] [Google Scholar]
- 21. Wang X, Qian X, Beitler JJ, Chen ZG, Khuri FR, et al. (2011) Detection of circulating tumor cells in human peripheral blood using surface-enhanced Raman scattering nanoparticles. Cancer research 71: 1526–1532. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22. Zavaleta C, De La Zerda A, Liu Z, Keren S, Cheng Z, et al. (2008) Noninvasive Raman spectroscopy in living mice for evaluation of tumor targeting with carbon nanotubes. Nano letters 8: 2800–2805. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23. Zavaleta CL, Hartman KB, Miao Z, James ML, Kempen P, et al. (2011) Preclinical evaluation of Raman nanoparticle biodistribution for their potential use in clinical endoscopy imaging. Small 7: 2232–2240. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24. van Dam GM, Themelis G, Crane LMA, Harlaar NJ, Pleijhuis RG, et al. (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-[alpha] targeting: first in-human results. Nature medicine 17: 1315–1319. [DOI] [PubMed] [Google Scholar]
- 25. Bird-Lieberman EL, Neves AA, Lao-Sirieix P, O'Donovan M, Novelli M, et al. (2012) Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus. Nature medicine 18: 315–321. [DOI] [PubMed] [Google Scholar]
- 26. Lutz BR, Dentinger CE, Nguyen LN, Sun L, Zhang J, et al. (2008) Spectral analysis of multiplex Raman probe signatures. ACS nano 2: 2306–2314. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Zavaleta CL, Smith BR, Walton I, Doering W, Davis G, et al. (2009) Multiplexed imaging of surface enhanced Raman scattering nanotags in living mice using noninvasive Raman spectroscopy. Proceedings of the National Academy of Sciences 106: 13511–13516. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Papoulis A, Pillai SU (2001) Probability, random variables and stochastic processes with errata sheet: McGraw-Hill Science/Engineering/Math.
- 29. Liu JTC, Helms MW, Mandella MJ, Crawford JM, Kino GS, et al. (2009) Quantifying cell-surface biomarker expression in thick tissues with ratiometric three-dimensional microscopy. Biophysical journal 96: 2405–2414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Tichauer KM, Samkoe KS, Sexton KJ, Hextrum SK, Yang HH, et al.. (2012) In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging. Molecular Imaging and Biology: 1–9. [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.